P3 Health Partners Inc. Form 8-K Summary
Business Context and Reporting Period
P3 Health Partners Inc. filed a Current Report on Form 8-K dated May 15, 2024, reporting a Nasdaq minimum bid price deficiency for its Class A common stock. The report was signed on May 20, 2024.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Material Change Versus the Prior Comparable Period
On May 15, 2024, Nasdaq notified the Company that its Class A common stock had closed below the required $1.00 minimum bid price for 31 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The filing does not provide a prior-period financial comparison.
Outlook, Risks, and Contingencies
- The deficiency letter has no immediate effect on the listing or trading of the common stock.
- The Company has until November 11, 2024, to regain compliance.
- Compliance requires the stock to close at or above $1.00 per share for at least 10 consecutive business days before the deadline.
- If the Company does not regain compliance, it may qualify for an additional 180-day compliance period if it satisfies Nasdaq’s other applicable requirements and submits written notice of its intent to cure the deficiency.
- If Nasdaq determines that the Company is not eligible or unlikely to cure the deficiency, the securities may become subject to delisting. The Company would have appeal rights following a delisting determination.
- Management stated that it will monitor the stock price and consider available options. The filing does not identify a specific remediation plan.
Important Facts for Investors to Verify
- Whether the common stock regained a closing bid price of at least $1.00 for 10 consecutive business days by November 11, 2024.
- Whether Nasdaq granted an additional compliance period or issued a delisting determination.
- Any corporate actions, including a potential reverse stock split or other measures, undertaken to restore compliance.
- The Company’s financial condition, liquidity, and operating performance, which are not provided in this filing and should be reviewed in its periodic SEC filings.